UTI - Mid Cap Fund

A Mid Cap Fund scheme from UTI Mutual Fund. Figures below are for the Direct · Growth plan (ISIN INF789F01UA6).

NAV ₹349.8477 on 16 November 2026.

Expense ratio

Total expense ratio 1.27% a year for the Direct · Growth plan, as AMFI published it on 29 October 2026: base expense ratio 0.85%, brokerage 0.08%, transaction costs 0.00%, statutory levies including GST 0.34%.

Returns and risk

PeriodReturn a yearVolatilityWorst fallSharpeSortino
1 year2.0%16.1%-13.6%-0.31-0.30
3 years11.6%15.5%-22.7%0.290.27
5 years10.5%15.3%-22.7%0.230.20
10 years15.1%16.6%-40.8%0.490.43

Category rank: 26th of 29 Direct-Growth funds in Mid Cap Fund, by 3-year Sortino ratio.

Largest holdings

Top 10 (September 2026 disclosure). Company shares make up 96.7% of the portfolio.

  1. Coforge Limited — 3.01%
  2. AU Small Finance Bank Limited — 2.75%
  3. Blue Star Limited — 2.55%
  4. Aurobindo Pharma Limited — 2.24%
  5. Ajanta Pharma Limited — 2.15%
  6. APL Apollo Tubes Limited — 2.11%
  7. The Federal Bank Limited — 1.98%
  8. The Phoenix Mills Limited — 1.95%
  9. Info Edge (India) Limited — 1.92%
  10. Shriram Finance Limited — 1.92%

Plans

Other funds in Mid Cap Fund

All 34 funds in Mid Cap Fund · Compare this fund with another

Past returns are history, not a forecast. XIRRO describes funds and portfolios; it is information, not investment advice.